“Following the positive initial Phase 2a data, we are preparing to advance the randomized Phase 2b study of HR+, HER2-, post-CDK4/6 inhibitor breast cancer patients,” said Dr. Stuart McIntosh, Chief Medic...
MATERIALS AND METHODS Chemicals CT7001 was provided by Carrick Therapeutics. Apalutamide, enzalutamide, darolutamide and bavdegalutamide were purchased from MedChemEx- press. Mibolerone was purchased from PerkinElmer. Cell lines LNCaP, C4-2, VCaP, DU145, PC3, PNT1A, BPH-1 cell lines were ...